ArticleCancer gene therapy2001
Development of lentiviral vectors for antiangiogenic gene delivery.
Article in Cancer gene therapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 54 citations in OpenAlex.
- Gene Therapy Approaches for Atherosclerosis Focusing on Targeting Lipid Metabolism and Inflammation.International journal of molecular sciences · 2025Review
- Epigenetic downregulation of the proapoptotic geneMolecular medicine reports · 2025Article
- Pseudotyped lentiviral vectors: Ready for translation into targeted cancer gene therapy?Genes & diseases · 2023Review
- Safety markers for rhabdomyosarcoma cells using anOncology letters · 2018Article
- Article
- Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targetingOncology letters · 2016Article
- Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.Biochimica et biophysica acta · 2015Review
- Promoter hypermethylation and silencing of tissue factor pathway inhibitor-2 in oral squamous cell carcinoma.Journal of translational medicine · 2014Article
- Anti-angiogenic gene therapy in the treatment of malignant gliomas.Neuroscience letters · 2012Review
- Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer.British journal of cancer · 2012Article
- Anti-tumor effect of lentivirus-mediated gene transfer of alphastatin on human glioma.Cancer science · 2011Article
- Effective in vivo and ex vivo gene transfer to intestinal mucosa by VSV-G-pseudotyped lentiviral vectors.BMC gastroenterology · 2010Article
- Transcriptional targeting of tumor endothelial cells for gene therapy.Advanced drug delivery reviews · 2009Review
- Suppression of renal cell carcinoma growth and metastasis with sustained antiangiogenic gene therapy.Human gene therapy · 2008Article
- Gene therapy targeting to tumor endothelium.Cancer gene therapy · 2007Review
- Antiangiogenic gene therapy of cancer: recent developments.Journal of translational medicine · 2004Article
- Cancer gene therapy: an awkward adolescence.Cancer gene therapy · 2003Review
- Noninvasive imaging of lentiviral-mediated reporter gene expression in living mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2003Article
- Cell physiology as a variable in gene transfer to endothelium.Current atherosclerosis reports · 2003Review
- Delivery of endostatin in experimental cancer therapy.International journal of experimental pathology · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Growth and metastasis of malignant tumors requires angiogenesis. Inhibition of tumor-induced angiogenesis may represent an effective cytostatic strategy. We have constructed recombinant self-inactivating lentiviral vectors expressing angiostatin and endostatin, and have tested their antiangiogenic activities. As VSV-G-pseudotyped lentiviral vectors showed low relative transduction titers on bovine aortic and human umbilical vein endothelial cells, it was difficult to achieve significant inhibition of endothelial cell growth by lentivirus-mediated antiangiogenic gene transfer directly to endothelial cells without concomitant vector-associated cytotoxicity. However, lentivirus vectors could efficiently and stably transduce T24 human bladder cancer cells that are relatively resistant to adenovirus infection due to loss of coxsackievirus-adenovirus receptor expression. Long-term expression and secretion of angiostatin and endostatin from lentivirus-transduced T24 cells resulted in significant inhibition of cellular proliferation on coculture with endothelial cells. This report represents the first use of lentivirus-based vectors to deliver the antiangiogenic factors, angiostatin and endostatin, and suggests the potential utility of antiangiogenic gene therapy with lentiviral vectors for the treatment of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.